Skip to main content
Equibles

CAXTON ASSOCIATES LLP

Position in RNA — Atrium Therapeutics, Inc.

CIK 2051323 LONDON, X0
Back to RNA Full portfolio

Position in RNA

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$594,893
+$3,538 QoQ
Shares Held
44,230
0.0% QoQ
Ownership
0.259%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#55
of 154 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RNA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CAXTON ASSOCIATES LLP holds $10,474,989 across 15 Biotechnology names. RNA ranks #8 (5.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LGND
Ligand Pharmaceuticals Inc
 5,854 $1,850,390
2 DNA
Ginkgo Bioworks Holdings, Inc.
 154,647 $1,532,551
3 AXSM
Axsome Therapeutics, Inc.
 4,290 $1,050,063
4 ZVRA
Zevra Therapeutics, Inc.
 70,048 $1,004,488
5 TECH
BIO-TECHNE Corp
 10,296 $727,412
6 MRVI
Maravai Lifesciences Holdings, Inc.
 112,479 $701,868
7 ARVN
Arvinas, Inc.
 82,313 $684,021
8 RNA
Atrium Therapeutics, Inc.
This page 		44,230 $594,893

All Filings in RNA

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $594,893 44,230
2026-03-31 $591,355 44,230